SRC and chronic myelogenous leukemia, BCR-ABL1 positive: Its ability to inhibit Src and Bcr-Abl kinases [67,69,70] is the main reason for its utility for the treatment of patients with chronic myeloid leukemia (CML), especially for those resistant to imatinib treatment [71].